Article Type
Original Study
Abstract
Objective The aim of this study was to assess CD95 expression on peripheral blood lymphocytes in patients with chronic hepatitis C virus (HCV) infection, both under interferon treatment and without interferon treatment, in comparison with a control group to assess its role in the pathogenesis of chronic hepatitis C disease. Background Egypt has the highest prevalence of HCV in the world, estimated nationally at 14.7%. Fas (APO-1/CD95)-mediated apoptosis plays an important role in liver cell destruction in viral hepatitis. Participants and methods Peripheral blood lymphocytes were isolated from 15 patients with chronic HCV under interferon treatment and from 20 patients with HCV without interferon treatment, and CD95 expression was analyzed by flow cytometry. The results were compared with those of normal control volunteers. Results The percentage of CD95 expression was significantly higher in patients with HCV without interferon treatment and in patients with HCV under interferon treatment compared with normal controls (27.09 ± 12.89 vs. 22.33 ± 11.42 vs. 11.09 ± 5.96, respectively). The percentage of CD95 expression did not differ significantly between patients with HCV without interferon treatment and patients with HCV under interferon treatment. Conclusion The increase in CD95 expression on PBMCs among HCV patients supports its role in the pathogenesis of chronic hepatitis C disease.
Recommended Citation
Essa, Enas Said; Waked, Imam Abd Elatif; Montaser, Laila Mahmoud; and Abd Elhameed, Rasha Mohammed
(2014)
"Expression of nuclear factor-κB1/P105 in Helicobacter pylori-induced gastric lesions,"
Menoufia Medical Journal: Vol. 27:
Iss.
4, Article 28.
DOI: https://doi.org/10.4103/1110-2098.149758
Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
